Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Inversago Pharma

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CANADA Canada

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              World Dairy Expo

              Participation Not Confirmed

              Update your events

              Inversago Pharma Closes US$35 M Series B Financing Round and Expands Board of Directors

              Contact the Supplier

              Lead Product(s): INV-101

              Therapeutic Area: Genetic Disease Product Name: INV-101

              Highest Development Status: Preclinical Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Forbion

              Deal Size: $35.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing September 08, 2020

              Details:

              Proceeds will be used to develop Inversago’s best-in-class peripherally-acting CB1 inverse agonist candidate INV-101 to clinical proof-of-concept, and advance the research on other selected compounds.

              ExCellThera

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CANADA Canada

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              World Dairy Expo

              Participation Not Confirmed

              Update your events

              IRICoR Makes Additional Investment in ExCellThera

              Contact the Supplier

              Lead Product(s): ECT-001

              Therapeutic Area: Genetic Disease Product Name: ECT-001

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: IRICoR

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Funding August 07, 2020

              Details:

              IRICoR's investment enabled ExCellThera to secure the co-funding required in connection with the grant awarded to it from the California Institute for Regenerative Medicine for a Phase 1 clinical trial using its ECT-001, for the treatment of severe sickle cell disease.

              PharmaCompass__DigitalAd